Viromed Medical AG: Revolutionary cold plasma therapy for the treatment of ventilator-associated pneumonia (VAP) shows 100% efficacy in an in vitro study with MRSA and human lung cells (alveoli)

EQS-News: Viromed Medical AG / Key word(s): Study Viromed Medical AG: Revolutionary cold plasma therapy for the treatment of ventilator-associated pneumonia (VAP) shows 100% efficacy in an in vitro study with MRSA and human lung cells (alveoli) 15.05.2025 / 18:10 CET/CEST The issuer is solely responsible for the content of this announcement. Viromed Medical AG: Revolutionary cold plasma therapy for the treatment of ventilator-associated pneumonia (VAP) shows 100% efficacy in an in vitro study with MRSA and human lung cells (alveoli)

• Study confirms the effectiveness and safety of cold plasma therapy

Pinneberg, May 14, 2025 - Viromed Medical AG ("Viromed", FSE: VMED; ISIN: DE000A3MQR65), a medical technology company and pioneer in cold plasma technology, today announced that scientists and medical researchers at Hannover Medical School presented groundbreaking results in the field of lung therapy: The use of cold plasma for the treatment of VAP showed significant in vitro efficacy and safety results.

The study, led by Prof. Dr. Hortense Slevogt, MHH and Helmholtz Centre for Infection Research (HZI), treated cultured methicillin-resistant Staphylococcus aureus (MRSA) and human lung cells (alveoli) with cold plasma. The results showed that cold plasma prevented the replication of MRSA bacteria by 100% and that all bacteria were killed within the defined therapeutic window. At the same time, it was shown that the alveoli were not damaged.

These results show that this new therapy is a highly effective method for the global treatment of pneumonia, as it is safe and does not develop resistance.

"The results are groundbreaking. The use of cold plasma offers a safe alternative or supplement to existing therapies and will significantly improve the prognosis of many patients," explains Prof. Dr. Hortense Slevogt, lead investigator.

"The study is a complete success and proves that the treatment with cold plasma in pneumonia is safe and revolutionary. In patients with ventilator-associated pneumonia, treatment with cold plasma will result in a significant reduction in the mortality rate in hospitals worldwide. This innovative method will therefore represent a significant advance in the treatment of severe lung diseases," says Uwe Perbandt, CEO of Viromed Medical AG, and adds: “The compelling results from this global study evaluating cold plasma in VAP strongly support Viromed's long lead and competitive edge over other players in this field.”